Will Walgreens (WBA) Go Bankrupt?

[View in browser]( [The Spill Logo] Proprietary Data Insights Financial Pros’ Top xxxx Stock Searches in the Last Month Rank Ticker Name Searches #1 [WBA]( Walgreens Boots Alliance 176 #2 [CVS]( CVS 45 #3 [PETS]( Petmed Express 5 #4 [RADCQ]( Rite Aid 2 #5 [CJJD]( China Jojo Drugstore 1 #ad [Master the Art of Investing with The Juice!]( Brought to you by [Stansberry Research]( [A.I. is a Tidal Wave - Here’s What to Buy]( [Stansberry Research - A.I. is a Tidal Wave - Here’s What to Buy]( Microsoft’s CEO Satya Nadella says A.I. is a “tidal wave.” One with even more potential than the internet. This is a huge claim. The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you’re buying Microsoft or NVIDIA to profit - you’re missing the big picture. After 50 years on Wall Street, I’m going public with another way to profit on the coming $7 trillion A.I. boom. This method has already uncovered multiple stocks that have gone up 100%, 200%, and even 300% (flying past NVIDIA, one of the top A.I stocks of 2023). And it just isolated another company. It’s an under-the-radar stock that already has a lucrative partnership with Microsoft - but has far more potential in the days ahead. To get its name and ticker symbol for free [Click here to know more]( Will Walgreens (WBA) Go Bankrupt? America was once a land of mom and pop pharmacies. Then, they consolidated under big chains like CVS (CVS) and Walgreens (WBA). Today, that business is in danger. CVS chose to acquire Aetna and become a holistic healthcare company. Rite Aid (RADCQ) filed for bankruptcy in late 2023. On paper, Walgreens looks like a steal. However, financial pros aren’t so sure. According, to our TrackStar data, money managers are spending time digging into Walgreens’ cash flows. The company is spending cash than it generates each year, putin the dividend in danger. So, we want to know…can they survive? Walgreens’ Business One of America’s largest pharmacy chains, Walgreens operates 8,631 stores, down from 8,817 stores last year. Each store contains a pharmacy as well as retail items including grocery, health, and beauty products. Revenues are segmented as follows: - Retail Pharmacy USA (60% of total revenues) - Focuses on prescription drugs and a variety of retail products, including health and wellness, beauty, personal care, and general merchandise. - Retail Pharmacy International (25% of total revenues) - Manages pharmacy-led health and beauty retail businesses outside the U.S. - Pharmaceutical Wholesale (15% of total revenues) - Operates under the Alliance Healthcare brand, supplying medicines and healthcare products to pharmacies, doctors, and health centers. Strategically, Walgreens Boots is committed to four priorities: - Transform and align the core business - Build its next growth engine, Walgreens Health - Focus the portfolio and optimize capital allocation - Build a high-performance culture and a winning team. This focus has led to Walgreens taking a 63% stake in VillageMD, a primary care clinic chain. In 2022, VillageMD acquired Summit Health as a means to gain a greater foothold in the primary, speciality, and urgent care markets. While that’s helped Walgreens grow its sales, lower reimbursement rates and slowndown in generic introduction has crimped the company’s margins. Ultimately, 2024 is going to be a make or break year for the company. Financials [Financials] Source: Stock Analysis Although revenues continue to grow, marginshave been on a steady decline. The company’s cost management program is expected to save $4.1 billion in 2024, with $1B in cost savings already underway, there have been no signs of this happening yet. According to management, the ‘trends’ in the retail market and lower reimbursement rates are to blame. However, leadership knows they need to improve cash flows. Their plans to reduce Capex by $600M and working capital by $500M this year certainly go a long way towards that end. There also hasn’t been discussion about reducing the debt, which sits at a massive $34 billion. With operating cash flows barely above $1 billion last year, this is a massive problem. Valuation [Valuation] Source: Seeking Alpha People point to 4.7% dividend yield and call Walgreens ‘cheap.’ In reality, it trades at a reasonable to expensive earnings and cash multiple. CVS is experiencing similar margin pressures, but has been able to reduce its expenses. And it trades at lower multiples. So, which would you rather own? Growth [Growth] Source: Seeking Alpha We find a similar story here, where CVS has seen better growth compared to Walgreens, on sales and earnings. CVS simply puts up better numbers overall than Walgreens. Profitability [Profit] Source: Seeking Alpha Now, Walgreens does have better gross margins. But it can’t seem to translate that to better EBIT. That’s why its returns on equity, assets, and total capital are abysmal for WBA. Our Opinion 2/10 In our opinion, Walgreens simply has too many problems to overcome. If they can start generating the $5-$8 billion in operating cash flow they did between 2018-2021 then we’d change our minds. But the headwinds don’t appear to be abating anytime soon. And the debt load is massive. We’d steer clear until the company starts to put together a plan that includes cutting the dividend and paying down the debt. [-facebook-share]( [-twitter-share]( [-linkedin-share]( [-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D609342?utm_medium=ic-nl&utm_source=116816 ) News & Insights Just Spilled - [Is Alibaba (BABA) Cheap Enough to Buy?]( - [Navigating Market Volatility: The Alt Advantage]( - [The Top 5 AI Software Stocks According to Financial Pros]( - [Why Fin Pros are Bullish on Target]( [News & Insights-facebook-share]( [News & Insights-twitter-share]( [News & Insights-linkedin-share]( [News & Insights-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D609342?utm_medium=ic-nl&utm_source=116816 ) [We want to hear from you. Let us know your thoughts by clicking here]( [Ads] [InvestingChannel Logo](#) Follow us on: [Facebook Logo]( [LinkedIn Logo]( [Twitter Logo]( [Instagram Logo]( To ensure delivery of all emails, [allow us on your list](. Manage your subscriptions with our [preference center](. [Unsubscribe here.]( View our privacy policy [here](. Copyright ©2024 InvestingChannel. All rights reserved. 1325 Avenue of the Americas, Floor 27 & 28 New York, New York 10019 Disclaimer: This is not investment advice. This InvestingChannel, Inc., newsletter is for information purposes only and is based on opinion. Futures, forex, stock, and options trading are not appropriate for all investors. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or methodology has ever been developed that can ensure returns or eliminate losses. InvestingChannel, Inc., makes no representation or implication that using any of the methodologies or systems in this newsletter will generate returns or insure against losses. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions. [Link](